A Phase I Study of the Combination of Azacitidine, Cyclophosphamide, Vincristine, and Rituximab in Relapsed and Refractory Lymphoma

被引：2
|
作者：
Moss, Jessica J. [1 ]
Howard, Dianna [1 ]
Van Meter, Emily [1 ]
Hayslip, John [1 ]
机构：
[1] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.1624.1624
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：706 / 706
页数：1
相关论文
共 50 条
  • [31] Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia
    Walker, Alison R.
    Klisovic, Rebecca B.
    Garzon, Ramiro
    Schaaf, Larry J.
    Humphries, Kristina
    Devine, Steven M.
    Byrd, John C.
    Grever, Michael R.
    Marcucci, Guido
    Blum, William
    LEUKEMIA & LYMPHOMA, 2014, 55 (06) : 1304 - 1308
  • [32] A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
    Fanale, Michelle A.
    Fayad, Luis E.
    Pro, Barbara
    Samaniego, Felipe
    Zachariah, Gracy
    Nunez, Cesar A.
    Ji, Yuan
    Younes, Anas
    BLOOD, 2008, 112 (11) : 1048 - 1048
  • [33] Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma
    Suzumiya, J
    Suzushima, H
    Maeda, K
    Okamura, S
    Utsunomiya, A
    Shibuya, T
    Tamura, K
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 79 (03) : 266 - 270
  • [34] Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma
    Junji Suzumiya
    Hitoshi Suzushima
    Kouichi Maeda
    Seiichi Okamura
    Atae Utsunomiya
    Tunefumi Shibuya
    Kazuo Tamura
    International Journal of Hematology, 2004, 79 : 266 - 270
  • [35] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul J.
    Koenig, Patricia A.
    Inwards, David J.
    Shah, Keith
    Ziesmer, Steven C.
    Feldman, Andrew L.
    Rao, Radha
    Gupta, Mamta
    Erlichman, Charles
    Witzig, Thomas E.
    LANCET ONCOLOGY, 2011, 12 (04): : 361 - 368
  • [36] Lenalidome in combination with rituximab for relapsed or refractory mantel cell lymphoma: Updated analysis of a phase 2 trial
    Wang, Yucai
    Dela Rosa, Maria Lourdes
    Zhou, Shouhao
    Badillo, Maria
    Addison, Alicia
    Zhang, Liang
    Lee, Hun Ju
    Romaguera, Jorge Enrique
    Wang, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Lenalidomide (Len) in combination with rituximab (R) demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory mantle cell lymphoma (MCL)
    Wang, Michael
    Fayad, Luis
    Hagemeister, Frederick
    Neelapu, Sattva
    Samuels, Barry
    Samanigo, Felipe
    Pro, Barbara
    Yi, Qing
    Bell, Neda
    Byrne, Catriona
    Weaver, Pam
    Hartig, Kim
    Knight, Robert
    Zeldis, Jerry
    Kwak, Larry
    Romaguera, Jorge
    BLOOD, 2007, 110 (11) : 755A - 755A
  • [38] Phase 1 Study of Lenalidomide and Ibrutinib in Combination with Rituximab in Relapsed and Refractory CLL and SLL
    Ujjani, Chaitra S.
    Wang, Hongkun
    Skarbnik, Alan P.
    Trivedi, Neel
    Ramzi, Pari
    Khan, Nadia
    Cheson, Bruce D.
    BLOOD, 2017, 130
  • [39] A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
    Cohen, Jonathon B.
    Wei, Lai
    Maddocks, Kami J.
    Heffner, Leonard T.
    Langston, Amelia
    Flowers, Christopher
    Devine, Steven M.
    Blum, Kristie A.
    BLOOD, 2015, 126 (23)
  • [40] Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
    Walter, Roland B.
    Medeiros, Bruno C.
    Gardner, Kelda M.
    Orlowski, Kaysey F.
    Gallegos, Leonel
    Scott, Bart L.
    Hendrie, Paul C.
    Estey, Elihu H.
    HAEMATOLOGICA, 2014, 99 (01) : 54 - 59
12345